What's In Store For Merck Stock In 2025?

1. Merck's stock fell about 10% in 2024, underperforming S&P 500. 2. Keytruda sales reached $28 billion, driving market share growth. 3. Gardasil sales declined due to competition and regulatory issues in China. 4. Merck's recent acquisitions target growth amid decreasing blockbuster revenue. 5. 2025 may see potential growth, especially with new FDA approvals pending.